PMA P900030

Device
CONTIGEN BARD COLLAGEN IMPLANT
Applicant
Allergan, Inc.
PMA number
P900030
Supplement
S011
Product code
LNM
Decision date
2009-10-02
Generic name
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
Approval order statement
APPROVAL FOR REVISED DIRECTIONS FOR USE (DFU) THAT INCLUDES INFORMATION FROM THE POST-APPROVAL STUDY ON COHORT C. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME CONTIGEN BARD COLLAGEN IMPLANT AND IS INDICATED FOR USE ONLY IN THE TREATMENT OF URINARY INCONTINENCE DUE TO INTRINSIC SPHINCTER DEFICIENCY (ISD, POOR OR NONFUNCTIONING BLADDER OUTLET MECHANISM) THAT MAY BE HELPED BY A LOCALLY INJECTED BULKING AGENT. CONTIGEN IMPLANT THERAPY SHOULD BE INITIATED ONLY IN PATIENTS WHO HAVE SHOWN NO IMPROVEMENT IN THEIR INCONTINENCE FOR AT LEAST 12 MONTHS.

Current openFDA PMA Record#

Device
CONTIGEN BARD COLLAGEN IMPLANT
Applicant
Allergan, Inc.
PMA number
P900030
Supplement
S011
Product code
LNM
Generic name
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
Decision date
2009-10-02
Decision code
APPR
Date received
2009-03-03
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Labeling Change - PAS
Approval order statement
APPROVAL FOR REVISED DIRECTIONS FOR USE (DFU) THAT INCLUDES INFORMATION FROM THE POST-APPROVAL STUDY ON COHORT C. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME CONTIGEN BARD COLLAGEN IMPLANT AND IS INDICATED FOR USE ONLY IN THE TREATMENT OF URINARY INCONTINENCE DUE TO INTRINSIC SPHINCTER DEFICIENCY (ISD, POOR OR NONFUNCTIONING BLADDER OUTLET MECHANISM) THAT MAY BE HELPED BY A LOCALLY INJECTED BULKING AGENT. CONTIGEN IMPLANT THERAPY SHOULD BE INITIATED ONLY IN PATIENTS WHO HAVE SHOWN NO IMPROVEMENT IN THEIR INCONTINENCE FOR AT LEAST 12 MONTHS.